New Drug's stomach acid effects tested in healthy volunteers

NCT ID NCT07446881

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 1 study tested how a single dose of ADV7103 affects stomach acid levels in 12 healthy adults, both with and without food. The goal was to understand how the drug behaves in the stomach. Results may help guide future dosing for people with distal renal tubular acidosis, a kidney condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ADV7103 (Sibnayal)

What this could lead to

If successful, this could help understand how ADV7103 works in the stomach, potentially improving dosing for kidney disease treatment.

What could go wrong

This is a very early Phase 1 study in only 12 healthy people, not patients. Results may not predict real-world effects or safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EFFECT OF ADV7103 ON GASTRIC PH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

distal renal tubular acidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Center Eugène Marquis, Laboratoire de Biologie

    Rennes, 35042, France